Table 3 Ongoing phase 3 clinical trials for intermediate or early stage hepatocellular carcinoma
From: Emerging agents and regimens for hepatocellular carcinoma
Trial | Settings | Arms | Clinicaltrials.gov identifier | Sponsor |
|---|---|---|---|---|
EMERALD-1 | intermediate stage, first line | TACE + durvalumab ± bevacizumab vs TACE + placebo | NCT03778957 | AstraZeneca |
CheckMate 9DX | Early stage, adjuvant therapy | Nivolumab vs placebo | NCT03383458 | BMS |
EMERALD-2 | Early stage, adjuvant therapy | Durvalumab + bevacizumab vs durvalumab + placebo vs placebo | NCT03847428 | AstraZeneca |
KEYNOTE-937 | Early stage, adjuvant therapy | Pembrolizumab vs placebo | NCT03867084 | MSD |
JUPITER 04 | Early stage, adjuvant therapy | Toripalimab vs placebo | NCT03859128 | Junshi |